On serendipity and innovations in public health

I briefly discuss about serendipity in the cases of penicillin discovery and Covid-19 vaccine research.

Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). SARS-CoV-2 has been spreading worldwide since December 2019, resulting in the ongoing COVID-19 pandemic with 237 million infections and 4.8 million deaths by 11 October 2021. While there are great efforts of global vaccination, ending this pandemic has been challenged by issues of exceptionally high viral transmissibility, re-infection, vaccine-breakthrough infection, and immune escape variants of concerns. Besides the record-breaking speed of vaccine research and development, antiviral drugs including SARS-CoV-2-specific human neutralizing antibodies (HuNAbs) have been actively explored for passive immunization. In support of HuNAb-based immunotherapy, passive immunization using convalescent patients’ plasma have generated promising evidence on clinical benefits for both mild and severe COVID-19 patients. Since the source of convalescent plasma is limited, the discovery of broadly reactive HuNAbs may have significant impacts on the fight against the COVID-19 pandemic. In this review, therefore, we discuss the current technologies of gene cloning, modes of action, in vitro and in vivo potency and breadth, and clinical development for potent SARS-CoV-2-specific HuNAbs.

The VirB System Plays a Crucial Role in Brucella Intracellular Infection

Brucellosis is a highly prevalent zoonotic disease caused by Brucella. Brucella spp. are gram-negative facultative intracellular parasitic bacteria. Its intracellular survival and replication depend on a functional virB system, an operon encoded by VirB1–VirB12. Type IV secretion system (T4SS) encoded by the virB operon is an important virulence factor of Brucella. It can subvert cellular pathway and induce host immune response by secreting effectors, which promotes Brucella replication in host cells and induce persistent infection. Therefore, this paper summarizes the function and significance of the VirB system, focusing on the structure of the VirB system where VirB T4SS mediates biogenesis of the endoplasmic reticulum (ER)-derived replicative Brucella-containing vacuole (rBCV), the effectors of T4SS and the cellular pathways it subverts, which will help better understand the pathogenic mechanism of Brucella and provide new ideas for clinical vaccine research and development.

What did we learn from the SARS-CoV-2 vaccine breakthrough infections?

The unprecedented pace in vaccine research and clinical development have provided a number of COVID-19 vaccines now widely used and many more candidates are currently in clinical development. While vaccination has been picking up, the emergence of variants and the continued spread of COVID-19 in some regions of the world have resulted in vaccine breakthrough infections. The early insights from epidemiological studies as well as genomic surveillance of vaccine breakthrough infections have provided unique and valuable data. Despite the ample paucity of data regarding breakthrough infections due to under-reporting and lack of uniform testing and reporting measures, here we try to navigate the different aspects of SARS-CoV-2 vaccines, breakthrough infections and the various other factors that could influence them.

Mathematical Modelling to Study Effect of Vaccination on Transmission of CORONA Virus

Since 2019 end, whole of the world is fighting for survival against Covid-19. To overcome the pandemic, global pharmaceutical sector started vaccine research. Early 2021, rose with a hope of vaccine discovery and few companies across the globe have invented and started manufacturing Covid-19 vaccine. As on date vaccination is playing a crucial role in curtaining the spread of this deadly virus caused disease. In this paper, a Compartmental Model is developed to study the spread of Covid-19 taking two different categories of human population into consideration. One is the vaccinated population and other is population without vaccination. Expressions for Reproduction Number are derived for Disease Free Equilibrium (DFE) and Endemic Equilibrium. Stability of the equilibria is also discussed.

Sex and Gender in COVID-19 Vaccine Research: Substantial Evidence Gaps Remain

Since the start of the COVID-19 pandemic there has been a global call for sex/gender-disaggregated data to be made available, which has uncovered important findings about COVID-19 testing, incidence, severity, hospitalisations, and deaths. This mini review scopes the evidence base for efficacy, effectiveness, and safety of COVID-19 vaccines from both experimental and observational research, and asks whether (1) women and men were equally recruited and represented in vaccine research, (2) the outcomes of studies were presented or analysed by sex and/or gender, and (3) there is evidence of sex and/or gender differences in outcomes. Following a PubMed search, 41 articles were eligible for inclusion, including seven randomised controlled trials (RCTs), 11 cohort studies, eight cross-sectional surveys, eight routine surveillance studies, and seven case series. Overall, the RCTs contained equal representation of women and men; however, the observational studies contained a higher percentage of women. Of 10 studies with efficacy data, only three (30%) presented sex/gender-disaggregated results. Safety data was included in 35 studies and only 12 (34%) of these presented data by sex/gender. For those that did present disaggregated data, overall, the majority of participants reporting adverse events were women. There is a paucity of reporting and analysis of COVID-19 vaccine data by sex/gender. Research should be designed in a gender-sensitive way to present and, where possible analyse, data by sex/gender to ensure that there is a robust and specific evidence base of efficacy and safety data to assist in building public confidence and promote high vaccine coverage.